- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02136342
Phase 1 Trial of Chlorogenic Acid in Patients With Advanced Cancer
October 19, 2014 updated by: Shi Yuankai, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1 Trial Evaluating Tolerability and Pharmacokinetics of Chlorogenic Acid for Injection in Patients With Advanced Cancer
The purpose of the study is to explore if chlorogenic acid is safe in patients with cancer.
Study Overview
Study Type
Interventional
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- advanced cancer with no effective treatment
- Karnofsky performance status no less than 70
- adequated organ function
- informed consent
Exclusion Criteria:
- allergic to chlorogenic acid
- persistent toxicities from previous treatment (no less than grade 2)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: chlorogenic acid
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of adverse events
Time Frame: within the first 60 days after the first dose of chlorogenic acid
|
within the first 60 days after the first dose of chlorogenic acid
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
dose-limiting toxicity
Time Frame: within the first 30 days after the first dose of chlorogenic acid
|
within the first 30 days after the first dose of chlorogenic acid
|
|
maximum tolerated dose
Time Frame: within the first 30 days after the first dose of chlorogenic acid
|
within the first 30 days after the first dose of chlorogenic acid
|
|
Area under the plasma concentration versus time curve (AUC) and Peak Plasma Concentration (Cmax) of chlorogenic acid
Time Frame: within the first 30 days after the first dose of chlorogenic acid
|
within the first 30 days after the first dose of chlorogenic acid
|
|
improvement in cancer-related symptoms and quality of life
Time Frame: within 1 year after the first dose of chlorogenic acid
|
within 1 year after the first dose of chlorogenic acid
|
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in number of red blood cell and level of hemoglobin
Time Frame: within 1 year after the first dose of chlorogenic acid
|
within 1 year after the first dose of chlorogenic acid
|
|
change in the diameters of lymph node metastasis
Time Frame: within 1 year after the first dose of chlorogenic acid
|
within 1 year after the first dose of chlorogenic acid
|
|
change in levels of tumor markers
Time Frame: within 1 year after the first dose of chlorogenic acid
|
within 1 year after the first dose of chlorogenic acid
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2014
Primary Completion (ANTICIPATED)
August 1, 2015
Study Registration Dates
First Submitted
May 9, 2014
First Submitted That Met QC Criteria
May 12, 2014
First Posted (ESTIMATE)
May 13, 2014
Study Record Updates
Last Update Posted (ESTIMATE)
October 21, 2014
Last Update Submitted That Met QC Criteria
October 19, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LYS-I-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.